Patents Assigned to AZURA OPHTHALMICS LTD.
-
Patent number: 11643429Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: May 9, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn
-
Patent number: 11634411Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: December 4, 2020Date of Patent: April 25, 2023Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Patent number: 11633410Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: April 21, 2021Date of Patent: April 25, 2023Assignee: AZURA OPHTHALMICS LTDInventors: Yair Alster, Omer Rafaeli, Kirsten Angela Macfarlane, Cary Reich, Shimon Amselem, Doron Friedman
-
Patent number: 11517586Abstract: Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS2) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.Type: GrantFiled: September 9, 2021Date of Patent: December 6, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Yair Alster, Charles Bosworth, Hila Epstein-Barash, Omer Rafaeli
-
Patent number: 11484516Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.Type: GrantFiled: March 28, 2018Date of Patent: November 1, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Shimon Amselem, Yair Alster, Doron Friedman, Omer Rafaeli
-
Patent number: 11459351Abstract: Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: April 5, 2021Date of Patent: October 4, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Robert M. Burk, Marc Gleeson, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls
-
Patent number: 11324775Abstract: Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).Type: GrantFiled: June 24, 2021Date of Patent: May 10, 2022Assignee: AZURA OPHTHALMICS LTD.Inventors: Charles Bosworth, Yair Alster, Hila Epstein-Barash, Omer Rafaeli, Marc Gleeson
-
Patent number: 11040062Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.Type: GrantFiled: April 13, 2017Date of Patent: June 22, 2021Assignee: AZURA OPHTHALMICS LTD.Inventors: Doron Friedman, Yair Alster, Omer Rafaeli, Shimon Amselem, Zakhar Nudelman
-
Patent number: 11013749Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: July 2, 2020Date of Patent: May 25, 2021Assignee: AZURA OPHTHALMICS LTD.Inventors: Yair Alster, Omer Rafaeli, Kirsten Angela Macfarlane, Cary Reich, Shimon Amselem, Doron Friedman
-
Patent number: 10875845Abstract: Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.Type: GrantFiled: June 17, 2020Date of Patent: December 29, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Ian Holmes, Yair Alster, Hila Barash, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Mark Richard Stewart, Robert M. Burk, Jonathan Dunn, Nicholas Chapman
-
Patent number: 10772899Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: September 5, 2019Date of Patent: September 15, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman
-
Patent number: 10688122Abstract: Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.Type: GrantFiled: September 28, 2016Date of Patent: June 23, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Shimon Amselem, Yair Alster, Doron Friedman, Omer Rafaeli
-
Patent number: 10588915Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: June 26, 2018Date of Patent: March 17, 2020Assignee: AZURA OPHTHALMICS LTD.Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman